Tag Archives: Aβ40

Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)

Summary Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults. As … Continue reading

Posted in Animal Studies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Novel Approach to Prevention of Alzheimer’s Disease Explored in Laboratory (Express / PloS One)

Summary Researchers at the University of California, San Diego, have explored a different approach to mainstream research into the prevention of Alzheimer’s Disease. It is believed that Alzheimer’s Disease develops when amyloid precursor protein (APP) gets cut-up by enzymes and … Continue reading

Posted in Animal Studies, For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Alzheimer’s Disease and the Clearance of Amyloid Beta Protein

[This article first appeared in: Dementia Newsletter RWHT Volume 1 Issue 6 January 2011]. Abstract Amyloid beta is normally released in the brain and cleared, but in Alzheimer’s disease the protein accumulates in the brain and causes cell death. The brains … Continue reading

Posted in For Researchers (mostly), In the News, Universal Interest | Tagged , , , | Leave a comment